MacroGenics (MGNX) 10-Q2015 Q3 Quarterly report

Filed: 4 Nov 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ADC, adjacent, Allergy, Assumption, Center, civil, complementary, comprehensively, conjugate, contractor, core, costly, Craig, criminal, debarment, Department, disallowance, discovery, dissemination, enoblituzumab, Europe, export, False, formation, franchise, gastric, harm, Health, hiring, HIV, illegal, immunodeficiency, import, improper, incorporate, infected, infection, integrity, introduced, latency, LLC, lobbying, National, NIAID, notified, package, procurement, protein, regained, reputational, reversing, routinely, sensitive, SOPHIA, suspension, Trident, uncover, underway, Venter

Removed: antigen, initiate, population, receivable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

MGNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

Certification of Principal Financial Officer
Pursuant to 18 U.S.C. 1350
(Section 906 of the Sarbanes-Oxley Act of 2002)

I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended September 30, 2015 of the Registrant (the Report), that:

(1) The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ James Karrels

Name: James Karrels

Date: November 4, 2015